Evidence map›Paper›PMID 25693996›Full record

ReviewThe Journal of antimicrobial chemotherapy2015

Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.

Md Abdul Alim Al-Bari

2 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of antimicrobial chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 227 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 6 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02874287 phase4completednot on this mapstarted 2017, after this paper: background citation

Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.

TypeinterventionalSponsorFirst Affiliated Hospital Xi'an Jiaotong UniversityRan2017 to 2019Enrolled35ConditionsCoronary Artery DiseaseArmsHydroxychloroquine Sulfate Tablets, Placebo Tablets
NCT04394416 phase3terminatednot on this mapstarted 2020, after this paper: background citation

Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2020 to 2025Enrolled21ConditionsCOVID-19ArmsImatinib, Placebo oral tablet
3 · Its place in the literature

Who cites it

227 citing papers in PubMed, 6 syntheses or guidelines pooled it, 461 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. [Chloroquine phosphate: therapeutic drug for COVID-19].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Trial
  9. Review
  10. Phenotypic Analysis of the Anti-Molecules (Basel, Switzerland) · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Md Abdul Alim Al-BariDepartment of Pharmacy, University of Rajshahi, Rajshahi 6205, Bangladesh alimalbari347@ru.ac.bd.
University of Rajshahi · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimalarial drugs (e.g. chloroquine and its close structural analogues) were developed primarily to treat malaria; however, they are beneficial for many dermatological, immunological, rheumatological and severe infectious diseases, for which they are used mostly today. Chloroquine and hydroxychloroquine, two of the most fascinating drugs developed in the last 50 years, are increasingly recognized for their effectiveness in myriad non-malarial diseases. In advanced research, chloroquine and hydroxychloroquine have been shown to have various immunomodulatory and immunosuppressive effects, and currently have established roles in the management of rheumatic diseases, lupus erythematosus (different forms) and skin diseases, and in the treatment of different forms of cancer. Recently, chloroquine analogues have also been found to have metabolic, cardiovascular, antithrombotic and antineoplastic effects. This review is concerned with the lysosomotropic, anti-inflammatory and immunomodulatory mechanisms of chloroquine, hydroxychloroquine, quinacrine and related analogues, and the current evidence for both their beneficial effects and potential adverse manifestations in various diseases.

Indexed as

AntimalarialsAntineoplastic AgentsCardiovascular AgentsChloroquineDrug-Related Side Effects and Adverse ReactionsDrug RepositioningHumansHydroxychloroquineImmunologic FactorsAntimalarialsAntineoplastic AgentsCardiovascular AgentsChloroquineHydroxychloroquineImmunologic Factorshydroxychloroquinelysosomotropic actionsquinacrineSLEtherapiestoxicity profiles

Identifiers

PMID25693996
PMCPMC7537707
OpenAlexW2014359324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.